JMS Co.,Ltd. logo

JMS Co.,Ltd.

7702.T

JPXHealthcareMedical - Instruments & Supplies

Latest quote

¥460

−¥2.00 · -0.43%

Aug 24, 2:31 PM JSTData delayed

7702.T company overview

Regular session · JST · Market data may be delayed.

Company profile

Company website

JMS Co., Ltd., established in 1947 and headquartered in Hiroshima, Japan, specializes in the development, manufacture, distribution, and global trade of a wide array of medical devices and pharmaceuticals. Its extensive product catalog serves both Japanese and international markets, addressing diverse medical needs. The company provides a comprehensive range of items for infusion and transfusion therapy, including infusion/transfusion sets (some featuring needle-free access ports), single-use needles and syringes, secure scalp vein sets, safe intravenous catheters, extension tubing, oral and enteral feeding systems, infusion and syringe delivery pumps, devices for administering semi-solid nutritional supplements, as well as blood bags, blood collection scales and mixers, high-frequency tube sealing equipment, and serum collection apparatus. For general medical use, JMS offers essential consumables for healthcare institutions such as surgical and examination gloves (both latex and plastic), treatment drapes, surgical gowns, protective masks and caps, drainage receptacles, and surgical adhesive tapes. Furthermore, JMS is a key supplier for hemodialysis and peritoneal dialysis, providing centralized dialysate delivery systems, hemodialysis units, AV fistula needles, systems designed to prevent accidental needlestick injuries, blood tubing sets for hemodialysis, dialyzers, pre-filled syringes, complete hemodialysis kits, single-patient dialysis devices, dialysis solutions for Continuous Ambulatory Peritoneal Dialysis (CAPD), and automated peritoneal dialysis equipment. The company also offers specialized products for cardiovascular therapy, which encompass cardiopulmonary support systems, membrane oxygenators, heat exchange units, pacemakers, microcatheters, and blood tubing sets for cardiopulmonary bypass.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
JP
CEO
Ryuji Katsura
Listed since
Jan 4, 2001
Employees
4,887

Market position

Day range

Current ¥460

52-week range

Current ¥460

Open
¥463
Previous close
¥462
Volume
15.2K
0.48× average
Average volume
31.77K
Average daily volume
Market cap
11.28B JPY
Beta
0.26
Market reference 1
50-day average
¥453.38
+1.46% above average
200-day average
¥440.48
+4.43% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
30.71B JPY
EV / EBITDA
7.28×
Earnings yield
-7.52%
Free cash flow yield
-8.56%

Profitability & efficiency

Return on equity
-1.88%
Return on assets
-0.94%
Return on invested capital
0.54%

Financial health

Current ratio
1.78×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends27%17%7%-4%Gross margin, FY2021: 24.53%Gross margin, FY2022: 22.90%Gross margin, FY2023: 21.59%Gross margin, FY2024: 22.83%Gross margin, FY2025: 23.32%Operating margin, FY2021: 1.68%Operating margin, FY2022: 1.14%Operating margin, FY2023: -0.41%Operating margin, FY2024: 1.25%Operating margin, FY2025: 0.58%Net margin, FY2021: 1.42%Net margin, FY2022: 0.44%Net margin, FY2023: -0.06%Net margin, FY2024: 0.13%Net margin, FY2025: -1.19%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 24.53%. Gross margin FY2022 22.90%. Gross margin FY2023 21.59%. Gross margin FY2024 22.83%. Gross margin FY2025 23.32%. Operating margin FY2021 1.68%. Operating margin FY2022 1.14%. Operating margin FY2023 -0.41%. Operating margin FY2024 1.25%. Operating margin FY2025 0.58%. Net margin FY2021 1.42%. Net margin FY2022 0.44%. Net margin FY2023 -0.06%. Net margin FY2024 0.13%. Net margin FY2025 -1.19%.

Income trends

Revenue

65.85B JPY-5.60%

Operating income

383M JPY-56.18%

Net income

−784M JPY−873M JPY
Income trends across reported periods76.8B JPY48.59B JPY20.38B JPY−7.84B JPYRevenue, FY2021: 58.17B JPYRevenue, FY2022: 63.74B JPYRevenue, FY2023: 65.29B JPYRevenue, FY2024: 69.75B JPYRevenue, FY2025: 65.85B JPYOperating income, FY2021: 980M JPYOperating income, FY2022: 724M JPYOperating income, FY2023: −268M JPYOperating income, FY2024: 874M JPYOperating income, FY2025: 383M JPYNet income, FY2021: 826M JPYNet income, FY2022: 281M JPYNet income, FY2023: −36M JPYNet income, FY2024: 89M JPYNet income, FY2025: −784M JPYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 58.17B JPY. Revenue FY2022 63.74B JPY. Revenue FY2023 65.29B JPY. Revenue FY2024 69.75B JPY. Revenue FY2025 65.85B JPY. Operating income FY2021 980M JPY. Operating income FY2022 724M JPY. Operating income FY2023 −268M JPY. Operating income FY2024 874M JPY. Operating income FY2025 383M JPY. Net income FY2021 826M JPY. Net income FY2022 281M JPY. Net income FY2023 −36M JPY. Net income FY2024 89M JPY. Net income FY2025 −784M JPY.
Metric (JPY)FY2025FY2024FY2023FY2022FY2021
Revenue65.85B JPY69.75B JPY65.29B JPY63.74B JPY58.17B JPY
Cost of goods sold50.49B JPY53.82B JPY51.2B JPY49.15B JPY43.9B JPY
Gross profit15.36B JPY15.93B JPY14.09B JPY14.6B JPY14.27B JPY
Research and development1.52B JPY1.32B JPY1.53B JPY
Selling, general, and administrative14.97B JPY15.05B JPY12.45B JPY12.12B JPY11.37B JPY
Operating expenses14.97B JPY15.05B JPY14.36B JPY13.87B JPY13.29B JPY
Interest income31M JPY19M JPY14M JPY12M JPY7M JPY
Interest expense407M JPY340M JPY220M JPY167M JPY159M JPY
Depreciation and amortization3.83B JPY3.89B JPY3.71B JPY3.59B JPY3.36B JPY
Operating income383M JPY874M JPY−268M JPY724M JPY980M JPY
Net income−784M JPY89M JPY−36M JPY281M JPY826M JPY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-15.48

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates22.864.75-13.35-31.46Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Q4 2024, reported Nov 7, 2024: actual -6.78, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Feb 7, 2025: actual 19.11, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 9, 2025: actual -4.9, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 8, 2025: actual -18.76, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 7, 2025: actual 10.98, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 6, 2026: actual 3.52, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 12, 2026: actual -27.71, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 7, 2026: actual -15.48, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates19.56B17.83B16.1B14.38BQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Q4 2024, reported Nov 7, 2024: actual 17.65B JPY, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Feb 7, 2025: actual 18.81B JPY, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 9, 2025: actual 17.11B JPY, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 8, 2025: actual 15.55B JPY, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 7, 2025: actual 16.67B JPY, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 6, 2026: actual 16.76B JPY, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 12, 2026: actual 16.87B JPY, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 7, 2026: actual 15.13B JPY, estimate —, surprise —, Comparison unavailable.

Corporate actions

Corporate action history

Stock split

Effective Sep 27, 2017

1:2

7702.T peers

ETFs holding 7702.T

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research 7702.T

research.disclaimer